Janssen signs MoU with Ministry of Investment of Saudi Arabia establishing framework for strategic partnership to boost the Kingdom’s healthcare and life sciences ecosystem

26

The partnership will advance both parties ambitions to provide quality healthcare and enhanced socio-economic outcomes for patients across Saudi Arabia

Riyadh, KSA: Janssen, one of the pharmaceutical companies of Johnson & Johnson today signed a Memorandum of Understanding (MoU) with the Ministry of Investment of Saudi Arabia (MISA), establishing a strategic partnership framework that will see the two entities co-develop a range of initiatives over the next 5 years.

The established framework spans four workstreams intended to deliver ecosystem enhancing initiatives across the Kingdom’s healthcare and life sciences sectors including enhancing the business environment and funding, supporting the data and clinical trials ecosystem, enabling human capital development and boosting innovation in the private sector.

Speaking on the partnership, Jamie Phares, Managing Director, Janssen GCC said: “Janssen has been a strategic partner to the Kingdom of Saudi Arabia for more than four decades. This MoU follows several others signed in 2020 and is intended to reinforce our commitment to enhancing the Kingdom’s healthcare and life sciences ecosystem. At Janssen we believe in the power of collaboration with our stakeholders to meet patient needs across all disease areas, fostering safer, healthier populations and stronger societies.

She added: “This MoU ensures that we are well placed to continue to support the Kingdom’s efforts to set the innovation agenda for the healthcare and life sciences sectors regionally.”

Commenting on the MoU, Mohammed Alquwaizani, General Manager KSA, Janssen GCC said: “At Janssen we are always seeking to establish new ways to meet patients’ needs and we never stop working to create a future where disease is a thing of the past.

“Saudi Arabia has made significant strides in the healthcare and life sciences space in recent years, and we look forward to continuing our work together to drive programs that will support the Kingdom’s ongoing efforts in becoming a knowledge-driven economy.”

The MoU was signed by Faysal Hamza, Deputy Minister at the Ministry of Investment, Kingdom of Saudi Arabia, and Jamie Phares, Managing Director, Janssen GCC, in a ceremony attended by senior officials from the Ministry of Investment, the Ministry of Health, other Saudi Arabia government agencies, as well as selected media.

Global and regional leaders representing Johnson & Johnson attended the event including Dr. Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson, Kris Sterkens, Company Group Chairman, Janssen EMEA, as well as Asgar Rangoonwala, Managing Director Emerging Markets, Janssen EMEA.

About the Janssen Pharmaceutical Companies:

At Janssen, we are creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at www.janssen.com/EMEA. Follow us at @JanssenEMEA